If you are interested in our services or solutions, please do not hesitate to contact us. We will get back to you as soon as possible.
Contact NowLiquid-liquid phase separation (LLPS) results in the formation of two distinct phases, containing a dilute phase and a dense phase. As the solution undergoing LLPS forms tiny droplets, the turbidity of the solution is altered. Thus, if phase separation of the protein occurs, the solution becomes milky or cloudy in appearance; otherwise, it remains clear. Mesoscale components in solution with diameters on the order of tens to hundreds of nanometers (nm) scatter visible light and can be detected by optical density measurements (typically at 340 nm or 400 nm) or by direct static light scattering.
Fig. 1. Working principle of turbidity assay. (Huang Y, et al., 2021)
Here, we use fixed wavelength optical density measurements to detect turbidity measurements performed on LLPS solutions. CD BioSciences offers turbidity meters, nephelometers, or spectrophotometers to determine the phase boundaries of protein and/or RNA systems by detecting changes in the turbidity of the solution. We measure turbidity according to the gradient of protein concentration of your project to detect the onset of turbidity, which is observed as a measurement of the saturation concentration of LLPS.
Turbidity measurements provide only a preliminary LLPS study that can detect multiple combinations.
Our turbidimetric services are widely used for liquid-liquid phase separation (LLPS) of proteins in in vitro chemical analysis. Faced with the common pitfalls of this assay due to being outside the linear range of detection, our experts explore simple sample dilution of insoluble aggregated protein samples or direct imaging of droplets to address these issues and improve the accuracy of turbidimetric assays. If you have any special requirements for our services, please feel free to contact us. We are looking forward to working together with your attractive projects.
Reference
CD BioSciences is a company conducting biomolecular condensates targeted innovative drugs. We integrate the latest advances in physics, chemistry, biology, and machine learning to address some of the most fundamental challenges in health and disease today.
Address:
Tel:
Email: